Alkermes (ALKS) Short-term Investments (2011 - 2026)
Alkermes' (ALKS) quarterly Short-term Investments came in at $160.3 million in Q1 2026, down 66.89% year-on-year from $484.2 million in Q1 2025, and down 78.08% on a QoQ basis from $731.2 million in Q4 2025.
Alkermes (ALKS) Short-term Investments (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Short-term Investments data on file, last reported at $160.3 million in Q1 2026.
- On a quarterly basis, Short-term Investments fell 66.89% year-over-year to $160.3 million in Q1 2026; TTM through Mar 2026 was $160.3 million, a 66.89% decrease from a year earlier, with the FY2025 full-year figure at $731.2 million, up 58.78% from the prior year.
- Short-term Investments for Q1 2026 stood at $160.3 million, down from $731.2 million in the prior quarter.
- Over the last five years, Short-term Investments for ALKS reached as high as $731.2 million in Q4 2025 and fell as low as $160.3 million in Q1 2026.
- Historically, Short-term Investments has averaged $365.2 million across 5 years, with a median of $324.3 million in 2024.
- Across the five-year window, Short-term Investments jumped 112.3% in 2024 and sank 66.89% in 2026, its largest moves.
- Year by year, Short-term Investments stood at $316.0 million in 2022, then gained by 0.01% to $316.0 million in 2023, then surged by 45.72% to $460.5 million in 2024, then surged by 58.78% to $731.2 million in 2025, then sank by 78.08% to $160.3 million in 2026.
- Per Business Quant data, the three most recent Short-term Investments figures were $160.3 million in Q1 2026, $731.2 million in Q4 2025, and $494.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.31 Mn |
| Dec 31, 2025 | 731.21 Mn |
| Sep 30, 2025 | 494.67 Mn |
| Jun 30, 2025 | 494.54 Mn |
| Mar 31, 2025 | 484.21 Mn |
| Dec 31, 2024 | 460.52 Mn |
| Sep 30, 2024 | 512.57 Mn |
| Jun 30, 2024 | 340.97 Mn |
| Mar 31, 2024 | 324.30 Mn |
| Dec 31, 2023 | 316.02 Mn |
| Sep 30, 2023 | 241.44 Mn |
| Jun 30, 2023 | 163.25 Mn |
| Mar 31, 2023 | 279.06 Mn |
| Dec 31, 2022 | 315.99 Mn |
| Sep 30, 2022 | 316.23 Mn |
| Jun 30, 2022 | 326.32 Mn |
| Mar 31, 2022 | 246.32 Mn |
| Dec 31, 2021 | 198.77 Mn |
| Sep 30, 2021 | 249.86 Mn |
| Jun 30, 2021 | 280.00 Mn |